Acazicolcept is under clinical development by Alpine Immune Sciences and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase I drugs for Type 1 Diabetes (Juvenile Diabetes) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Acazicolcept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acazicolcept overview

Acazicolcept is under development for the treatment of multiple sclerosis, arthritis, inflammatory bowel disease, hemophagocytic lymphohistiocytosis, uveitis, type I diabetes, systemic lupus erythematosus. It acts by targeting inducible T-cell costimulator (ICOS) and T cell-specific surface glycoprotein CD28 (CD28). It is administered by intravenous or subcutaneous routes as an injection. The drug candidate is developed based on the variant immunoglobulin domain (vIgD) platform technology. It is a fusion protein, synthesized by combining vIgDs with antibody Fc domains.

It was also under development for psoriatic arthritis, graft versus host disease (GVHD) and rheumatoid arthritis, sicca syndrome (sjogren).

Alpine Immune Sciences overview

Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Alpine is headquartered in Seattle, Washington, the US.

For a complete picture of Acazicolcept’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.